Review
Open access
Sep 2026
CDK4/6 Inhibitors in the Management of Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Advanced Breast Cancer in Indonesia: Challenges, Opportunities, and Recommendations.
A review underscores the critical role of CDK4/6 inhibitors in the treatment of HR+/HER2- ABC, with a particular focus on Indonesian patients, and supports consideration of these agents for inclusion in national clinical guidelines to enhance patient outcomes.
S. S. Panigoro, S. Haryono, P. Prihantono et al.
· Asia-Pacific Journal of Clin... · 0 citations